Robust Phase III data from AstraZeneca’s Imfinzi in patients with unresectable lung cancer

 

AstraZeneca has today announced results from its relevant Phase-III Pacific clinical trial, testing immunotherapy Imfinzi in patients with advanced-stage, unresectable lung cancer. The results show that AstraZeneca’s blockbuster significantly improves the patient’s life expectancy, even when the cancer has reached stage 3 or 4.  The company’s shares have soon reacted to the positive news by rising over 2% (London).

(Source: AstraZeneca)